Sees Q4 product ales $49M-$50M, consensus $46.82M. "Assertio’s preliminary 2022 results demonstrated our ability to scale net product sales and generate substantial cash flow to fund our growth objectives, both organic and strategic," said Dan Peisert, Chief Executive Officer. "We ended 2022 with cash and cash equivalents of $64.9 million, which was greater than our September cash balance even after funding $25 million of asset purchase payments for Otrexup and Sympazan in the fourth quarter."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ASRT:
- Assertio to Participate in the 2023 Winter Wonderland Best Ideas Conference
- Assertio Holdings management to meet with Lake Street
- Assertio provides the LGS Foundation $100,000 educational grant
- Assertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) Foundation
- Assertio Holdings, Inc. Announces FDA Orange Book Listing for New Sympazan® Oral Film Patent
